258
￭ S-429 ￭
Comparison of adiposity indices for the prediction of fatty liver disease in obese men
1부산대학교병원, 2삼성창원병원
*
송보혜
1, 김정미
2, 남현열
3, 김보현
4, 김인주
5Objective: To compare adiposity indices and liver fluorine-18-labeled fluoro-2-deoxy-D-glucose (FDG) uptake for the prediction of fatty liver disease (FLD) in a population with metabolically healthy obesity (MHO) and metabolically unhealthy obese men (MUO).
Methods: We retrospectively reviewed data from 264 consecutives males who had undergone general health check-ups including FDG positron emis- sion tomography/computed tomography (PET/CT) scans. Participants were stratified by BMI (cutoff value, 25.0 kg/m2) and metabolic health state (using Wildman criteria) as MHO, MUO, metabolically healthy non-obese (MHNO), and metabolically unhealthy non-obese (MUNO). Five anthro- pometric indices were measured (Waist Circumference, WC; Waist-to-Hip Ratio, WHR; Body Mass Index, BMI; Body Fat Mass, BFM; and Conicity Index). A radiologist determined the presence of fatty liver using abdominal ultrasonography interpretation.
Results: The proportions of each group were 20.5% (MHO), 60.6% (MHNO), 14.4% (MUHO), and 4.5% (MUNO), respectively. FLD was most com- mon (86.8%) and the highest hepatic FDG uptake in MUHO group compared with other 3 groups. Among 5 anthropometric indices, WC showed the strongest correlations with FLD in MHO and MHNO. WC showed 0.84 (95% confidence interval 0.73–0.94) probability in MHO and 0.74 probability (95% CI, 0.64–0.85) in MHNO of identifying the presence of hepatic steatosis according to receiver operating characteristic curve (ROC) analysis.
Conicity index showed 0.72 probability (95% CI, 0.38 -0.94) of identifying the presence of hepatic steatosis in MUNO group.
Conclusions: Adiposity indices are associated with FLD in men in different degrees. WC are the most powerful predictor presence of FLD in men with MHO and MHNO. These results suggest that different surrogate indices of visceral adiposity may be needed for prediction of FLD in patients with various metabolic and obesity phenotypes.
￭ S-430 ￭
The increased soluble CD36(sCD36) level in patients with type 2 diabetes
계명대학교 동산의료원 내분비내과
*
이규민, 김한별, 조난희, 한유진, 김민지, 박창현, 조호찬
Background: In type 2 diabetes(T2DM) Patients, the atherosclerosis is the major cause of morbidity and mortality. As is well known the low-density lipoprotein (LDL) is significantly increasing in diabetes patients and LDL is the most important thing to make atherosclerosis. CD36 is scavenger re- ceptor for oxidized LDL so that means CD36 expression is upregulated by oxidized LDL. The aim of this study is to investigate the association with sCD36 and diabetes. And also there is a lack of study that compare to prediabetes and diabetes patient. We should also search about it. Methods: Study subjects comprised of those with normal glucose tolerance(n＝20), prediabetes(IFG, IGT, n＝20) and type 2 diabetes(n＝40). The biochemical parame- ters were analyzed using auto-analyzer, and the level of sCD36 was estimated using an ELISA kit Results: Individuals with type 2 diabetes showed higher level of sCD36(14.22±1.47) was observed than that of normal glucose tolerance(11.44±1.58) and prediabetes group(11.44±1.58)(p＜0.001).
However, there were no significant differences of sCD36 level between normal glucose tolerance/prediabetes group and type 2 diabetes group (p＝
0.355). Finally, in stepwise multiple-regression analysis, HbA1c independently contributed to the level of sCD36(adjusted R2＝0.457, p＜0.001).
Conclusion: sCD36 shows a higher level in type2 diabetes group when compare to normal/prediabetes group. This study shows that there is a positive correlation with HbA1C and sCD36. sCD36 was significantly more prevalent in type 2 diabetes patients with poor glucose control.
